Innovation

How is the pharmaceutical industry integrating innovations from adjacent industries to enhance drug development and production?

Pharma's Almanac

RNA

Optimized Residual dsRNA Detection for mRNA Therapeutics

Eunseo (Ency) Lee, Ph.D; Namhyun Kim; Hwanjun Yoon, Ph.D.; Sukhwan Kim; Ahyeon Hwang

Samsung Biologics

Developability

Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform

Heonchang Lim

Samsung Biologics

Sequence Variants

Accelerating Protein Sequence Variant Analysis

Kyoungmin Lee; Yunjeong Heo; Jongbae Park

Samsung Biologics

Changing Roles

How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?

Pharma's Almanac

Global Access

How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications?

Pharma's Almanac

Regulatory

Building a Path to Approval with Effective Regulatory Support

Mira Han

Samsung Biologics

Trusted Partnerships

Partnerships for Success

Ryan Lee

Samsung Biologics

Digitalization

How can Life Science Technology Providers Support the Pharmaceutical Industry in the Transition Toward More Digitally Connected Operations?

Pharma's Almanac

Investment

What are the Current Investment Trends in the Pharmaceutical Industry, and How are They Influencing the Sector’s Direction?

Pharma's Almanac

Down Stream Processing

Expediting Biologics Drug Development: Downstream Strategies to Accelerate Preclinical Development Timelines

Songyoung Kim

Samsung Biologics

Commitment to ESG Principles

How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?

Pharma's Almanac

Accelerating Product Development

What strategies are being employed to accelerate product development and commercialization without compromising quality?

Pharma's Almanac

Bispecific Antibodies

Accelerating the Development and Production of High-Quality Bispecific Antibodies

Dongyoung Park

Samsung Biologics

Drug Development

Podcast: Insights from CDO Experts from Samsung Biologics

Jiyeon Lee; Hyelyoung Jang

Samsung Biologics

Roundtable

What do you see as the most significant regulatory decision or guidance on the horizon for 2024 (or beyond)?

Pharma's Almanac

Roundtable

What Do You Think Was The Single Most Consequential Event Or Result In Pharma/Biopharma In 2023?

Pharma's Almanac